Cosmetic composition

Abstract

Composition comprising as active ingredient birch sap, maple sap, willow leaf extract and ginkgo biloba leaf extract.

Description

Title of the invention: Cosmetic composition FIELD OF THE INVENTION

[0001] The technical sector of the present invention relates to compositions, in particular cosmetic and dermatological compositions, comprising birch sap, maple sap, willow leaf extract and ginkgo biloba leaf extract. STATE OF THE ART

[0002] At the interface with air, the skin is the target of several environmental stresses, such as pollution and UV radiation. Air pollutants penetrate the skin directly or indirectly and induce several biochemical changes such as an increase in the production of reactive oxygen species, but also a decrease in cell proliferation, antioxidants and ATP concentrations. Clinically, the effects of pollutants lead to an exacerbation of skin aging processes, symptoms of inflammatory diseases and deregulation of skin hydration. The combination of UV radiation and pollutants could exacerbate the biochemical and clinical effects of air pollutants.

[0003] Birch is a tree belonging to the Betulaceae family growing in humid, swampy or peaty forests. It is traditionally used to give a pale color to the skin. Document WO2021031750A1 for example relates to a cosmetic skin whitening composition comprising birch sap.

[0004] Birch sap also has antioxidant, detoxifying, protective properties against the effects of ultraviolet rays, skin regenerating, moisturizing and soothing properties.

[0005] Maple is a tree belonging to the Aceraceae family that grows in humid, cool, high but sunny areas. It is traditionally used for its therapeutic properties to cover wounds, abscesses and to treat eye disorders.

[0006] Maple sap also has antibacterial, antidiabetic, moisturizing, exfoliating, antioxidant and purifying properties.

[0007] Willow is a tree of the Samicaceae family growing in temperate regions. It is known as the aspirin tree because it contains a large number of salicylic derivatives and is used to treat certain pains and sleep disorders. It can also be used to treat warts and corns. Document US2012082839 for example relates to a composition for the treatment of pain comprising in besides willow leaf extract.

[0008] Willow leaf extract further exhibits antioxidant and soothing properties.

[0009] Ginkgo biloba is a tree of the Ginkgoaceae family. It has historically been used in China as a dietary supplement for its benefits on the brain, legs, eyes, and heart. Ginkgo biloba leaves are generally used as an infusion but also extracted to combat aging. Document WO9515172A1, for example, concerns an extract of gingko biloba leaves, its production process, and its use in cosmetics and dermatology.

[0010] Ginkgo biloba leaf extract also has antioxidant, soothing, skin regenerative properties by stimulating the synthesis of collagen and fibronectin (Kim et al., 1997), phytoprotective and slimming properties.

[0011] There is currently no composition comprising in combination birch sap, maple sap, willow leaf extract and ginkgo biloba leaf extract. Statement of the invention

[0012] The invention relates to a composition comprising as active ingredient birch sap, maple sap, willow leaf extract and ginkgo biloba leaf extract.

[0013] Advantageously, the composition comprises between 10% and 50% by mass of birch sap.

[0014] Advantageously, the composition comprises between 10% and 50% by mass of maple sap.

[0015] Advantageously, the composition comprises between 3% and 20% by mass of willow leaf extract.

[0016] Advantageously, the composition comprises between 3% and 20% by mass of ginkgo biloba leaf extract.

[0017] According to a characteristic of the invention, the composition also comprises extract of small chili fruit.

[0018] According to another characteristic of the invention, the composition is in the form of a gel, a lotion, a mousse, a balm, a cream, a spray or a serum.

[0019] A very first advantage of the composition according to the present invention is that it makes it possible to increase the expression of hyaluronic acid at the level of the papillary dermis. It therefore has properties of hydration and repair of the skin tissue and participates in the cellular proliferation of the cells of the skin tissue.

[0020] Another advantage of the composition according to the present invention is that it allows to increase the expression of PINK1 in epidermal cells. It therefore participates in maintaining cellular homeostasis in skin tissue cells.

[0021] Yet another advantage of the composition according to the present invention is that it makes it possible to reduce the expression of Nrf2 at the level of the epidermis. It therefore has antioxidant properties.

[0022] Yet another advantage of the composition according to the present invention is that it makes it possible to increase the expression of oxytocin at the level of the cells of the epidermis. It therefore makes it possible to participate in growth and proliferation and also to fight against inflammation of the skin tissue.

[0023] Yet another advantage of the composition according to the present invention is that it makes it possible to increase the ATP concentration in the cells of the epidermis. It therefore makes it possible to promote proliferation and inhibit terminal differentiation of keratinocytes. The composition according to the invention also makes it possible to participate in the repair of the skin barrier. Brief description of the drawings

[0024] Other characteristics, advantages and details of the invention will be better understood on reading the additional description which follows in relation to the drawings in which:

[0025] [Fig.l] illustrates the results of the labeling and therefore of the expression of hyaluronic acid in the papillary dermis and the epidermis,

[0026] [Fig.2] illustrates the results of the labeling and therefore of the expression of PINK1 in the epidermis,

[0027] [Fig.3] illustrates the results of the labeling and therefore of the expression of Nrf2 in the epidermis, and

[0028] [Fig.4] illustrates the results of the labeling and therefore of the expression of oxytocin in the epidermis.

[0029] DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

[0030] As previously mentioned, the invention relates to a composition comprising birch sap, maple sap, willow leaf extract and ginkgo biloba leaf extract.

[0031] The Birch sap according to the invention further comprises:

[0032] - oligosaccharides such as glucose, fructose, galactose, sucrose and inositol, - essential minerals such as calcium, zinc, magnesium, potassium and sodium, - organic acids such as malic acid, - amino acids, and - conservatives.

[0033] The maple sap according to the invention further comprises:

[0034] - oligo- and polysaccharides such as fructose, glucose, rinulin, neokestose and sucrose, - phenolic compounds such as phenolic acid, - organic acids such as citric acid, malic acid, acid oxalic acid, quinic acid and succinic acid, - minerals such as calcium and potassium, - amino acids and proteins such as glutamic acid, histidine, isoleucine, leucine, lysine, methionine, tyrosine and tryptophan,

[0035] The willow leaf extract according to the invention further comprises:

[0036] - phenolic compounds such as flavonoids and its derivatives, phenolic acids and procyanidins, and

[0037] The ginkgo biloba leaf extract according to the invention further comprises:

[0038] - phenolic compounds such as flavonoids and its derivatives, proanthocyanidins and tannins, - oligo- and polysaccharides such as mannan, - vitamins such as vitamin C, - minerals such as calcium, magnesium, manganese, potassium, selenium and sodium, - amino acids and proteins, and

[0039] In view of the individual properties of the extracts from these trees, the inventors devised a composition combining these extracts in order to treat the skin. They were thus surprised to find that this composition had a surprising beneficial effect on the skin.

[0040] In order to demonstrate this effect, the inventors then analyzed the biological activity of the composition according to the invention on ex vivo human skin explants by histological, biochemical and genomic studies and realized that the composition according to the invention induced at the level of human skin:

[0041] - an increase in the synthesis of hyaluronic acid, - an increase in the expression of PINK1, - a decrease in the expression of Nrf2, - an increase in ATP synthesis, - an increase in oxytocin expression, - regeneration of the skin barrier, - differentiation of keratinocytes, - formation of the stratum corneum, - induction of genes coding for defensins, lipocalin and cathelicidin, and - repression of genes coding for pro-inflammatory cytokines or chemokines.

[0042] The histological and biochemical studies further consist of analyzing the effect of the composition according to the invention on the expression of hyaluronic acid, PINK1, Nrf2 and oxytocin by cells originating from human skin explants as well as their ATP concentration.

[0043] To do this, the inventors tested the effect of the following products:

[0044] - the product PI comprising 40% by mass of maple sap, 40% by mass of birch sap, 10% by mass of willow leaf extract and 10% by mass of gingko biloba leaf extract, - product P2 comprising 20% ​​by mass of maple sap, 20% by mass of birch sap, 5% by mass of willow leaf extract, 5% by mass of gingko biloba leaf extract and 50% by mass of glycerin, and - product E comprising 50% by mass of glycerin and 50% by mass of distilled water.

[0045] The inventors prepared explants of human skin from an abdominal plastic surgery and divided them into four batches:

[0046] - batch T0 corresponding to the plasty control and comprising 3 explants, - batch T corresponding to the control and comprising 6 explants, - batch E corresponding to the batch treated with product E and comprising 6 explants, - the PI batch corresponding to the batch treated with the PI product and comprising 6 explants, - batch P2 corresponding to the batch treated with product P2 and comprising 6 explants.

[0047] Each skin explant was kept alive in a culture medium at a temperature of 37°C in a humid atmosphere enriched with 5% CO2.

[0048] At T = 0 days (D0), T = 1 day (D1), T = 4 days (D4), T = 6 days (D6) and T = 7 days (D7), 5 μL of products E, PI and P2 were respectively applied topically to the explants of batches E, PI and P2.

[0049] At D0, the 3 explants of batch T0 were removed and cut into three parts. The first was fixed in a buffered formalin solution, a second part was frozen at -80°C for histological analysis and a third part was frozen at -80°C for biochemical analysis.

[0050] At T = 5 days (D5) and T = 8 days (D8), 3 explants from batches T, E, PI and P2 were taken and treated in the same way as the explants from batch T0.

[0051] After 24 hours in buffered formalin, the samples were dehydrated and impregnated in paraffin and then put into blocks. 5 μm sections were made and mounted on histological glass slides.

[0052] The general morphology of the dermal and epidermal structures was analyzed on paraffin sections after staining with Masson trichrome Goldner variant and evaluated by microscopic examination.

[0053] The expression of hyaluronic acid in the papillary dermis and the epidermis was observed by performing immunolabeling of hyaluronic acid from batches T0, T at D5 (TJ5) and D8 (TJ8), E at D5 (EJ5) and D8 (EJ8), PI at D5 (P1D5) and D8 (P1D8) and P2 at D5 (P2D5) and D8 (P2D8). The hyaluronic acid was labeled on formalin paraffin sections with a HABP (Hyaluronic Acid Binding Protein) diluted to 1 / 800 in 0.3% PBS-BSA for 1 hour at room temperature with a biotin / streptavidin amplifier system and revealed in VIP. The immunolabeling is then evaluated by microscopic observation.

[0054] The expression of PINK1 in the epidermis was observed by performing immunolabeling of PINK1 from batches T0, T at D5 (TJ5) and D8 (TJ8), E at D5 (EJ5) and D8 (EJ8), PI at D5 (P1J5) and D8 (P1J8) and P2 at D5 (P2J5) and D8 (P2J8). PINK1 was labeled on paraffin sections with an anti-PINK1 monoclonal antibody diluted 1 / 100 in PBS-BSA 0.3% overnight at room temperature of 4°C with a biotin / streptavidin amplifier system and revealed in VIP. The immunolabeling is then evaluated by microscopic observation.

[0055] The expression of Nrf2 in the epidermis was observed by performing immunolabeling of Nrf2 from batches T0, T at D5 (TJ5) and D8 (TJ8), E at D5 (EJ5) and D8 (EJ8), PI at D5 (P1J5) and D8 (P1J8) and P2 at D5 (P2J5) and D8 (P2J8). Nrf2 was labeled on paraffin sections with an anti-Nrf2 monoclonal antibody diluted to 1 / 400 in PBS-BSA 0.3%-Tween 20 at 0.05% for one hour at room temperature with a biotin / streptavidin amplifier system and revealed in VIP. The immunolabeling is then evaluated by microscopic observation.

[0056] The expression of oxytocin in the epidermis was observed by performing immunolabeling of oxytocin in batches T0, T at D5 (TJ5) and D8 (TJ8), E at D5 (EJ5) and D8 (EJ8), PI at D5 (P1D5) and D8 (P1D8) and P2 at D5 (P2D5) and D8 (P2D8). Oxytocin was labeled on frozen sections with an anti-oxytocin monoclonal antibody diluted to 1 / 200 in PBS-BSA 0.3%-Tween 20 at 0.05% for one hour at room temperature with a biotin / streptavidin amplifier system and revealed in VIP. The immunolabeling is then evaluated by microscopic observation.

[0057] The ATP assay was carried out on batches T0, T at D5 (TJ5) and D8 (TJ8), E at D5 (EJ5) and D8 (EJ8), PI at D5 (P1D5) and D8 (P1D8) and P2 at D5 (P2D5) and D8 (P2D8). Frozen skin explants were ground and then subjected to cell disruption with ultrasound. After centrifugation at + 4000 rpm, at 18°C, the proteins were measured. in the supernatant by a Bradford technique. The ATP of the explants was quantified using an ATP assay kit and a fluorimeter.

[0058] In Figures 1 to 4, TF corresponds to very weak marking, F to weak marking, M to moderate marking, AN to fairly clear marking, N to clear marking, TH to very clear marking and Fo to strong marking.

[0059] [Fig.l] illustrates the results of the labeling and therefore of the expression of hyaluronic acid in the papillary dermis and the epidermis.

[0060] Hyaluronic acid is a non-sulfated glycosaminoglycan consisting of repeats of D-glucuronic acid and DN-acetylglucosamine. It is one of the major components of the skin and is notably involved in several cellular processes including hydration, skin tissue repair and cell proliferation. For example, under the chronic action of UV rays, the synthesis of hyaluronic acid is reduced while the activity of hyaluronidases remains unchanged. A significant degradation of hyaluronic acid is thus observed. HABP (Hyaluronic Acid Binding Protein) is a protein that links hyaluronic acid to other components of the extracellular matrix of the dermis, including proteoglycans. It is used in dermatological research to visualize hyaluronic acid within skin tissue.

[0061] It can be seen in [Fig.l] that the labeling of hyaluronic acid at the level of the epidermis is weak on batch T0, weak to moderate on batches TJ8, EJ8, P1J8 and P2J8 and moderate on batches TJ5, EJ5, P1J5 and P2J5.

[0062] Thus, whether at D5 or D8, the products PI and P2 do not induce modifications in the expression of hyaluronic acid compared to the control T and the product E.

[0063] The labeling of hyaluronic acid at the level of the papillary dermis is weak to moderate on batches TJ8, EJ8, P1J8 and P2J8, moderate on batches TJ5, EJ5, and P2J5 and quite clear on batches T0 and P1J5.

[0064] Thus, the PI product induces a moderate increase in the expression of hyaluronic acid compared to the control T and to the product E at the level of the papillary dermis.

[0065] The composition according to the invention makes it possible to increase the expression of hyaluronic acid at the level of the papillary dermis. It therefore has properties of hydration and repair of the skin tissue and participates in the cellular proliferation of the cells of the skin tissue.

[0066] [Fig.2] illustrates the results of the labeling and therefore of the expression of PINK1 in the epidermis.

[0067] PINK1 (P-TEN Induced Putative Kinase 1) is a protein involved in the mitophagy mechanism, which is a process of selective autophagy of damaged and non-functional mitochondria. It specifically accumulates on the surface of the outer membrane of damaged mitochondria whose electrochemical potential is disturbed. Within skin tissue, the mitophagy process is stimulated by oxidative stress, linked to the accumulation of reactive oxygen species contributing to the elimination of damaged mitochondria and the maintenance of cellular homeostasis. PINK1 is also linked to anti-aging cellular mechanisms, particularly in the skin.

[0068] The labeling of PINK1 at the level of the epidermis is weak on batch T0, weak to moderate on batches TJ8 and EJ8, moderate on batches TJ5 and EJ5 and moderate to fairly clear on batches P1J5, P2J5, P1J8 and P2J8.

[0069] Thus, whether at D5 or D8, the PI and P2 products induce an increase in the expression of PINK1 compared to the control T and the product E.

[0070] The composition according to the invention makes it possible to increase the expression of PINK1 at the level of the cells of the epidermis. It therefore participates in maintaining the cellular homeostasis of the cells of the skin tissue and has anti-aging properties.

[0071] [Fig.3] illustrates the results of the labeling and therefore of the expression of Nrf2 in the epidermis.

[0072] Nrf2 is a transcription factor with a key role in the response to oxidative stress and is constitutively expressed in a large group of cells and tissues. Under the action of oxidative stress, including exposure to UVs, Nrf2 is phosphorylated promoting its successive translocation from the cytoplasm to the nucleus. Once translocated into the nucleus, Nrf-2 is able to bind to DNA at a specific region, also known as HARE (Human Antioxidant Response Element). Nrf2 plays in particular a key role in the protection of keratinocytes against UV-induced alterations.

[0073] The labeling of Nrf2 at the level of the epidermis is weak to moderate on batches TJ8, EJ8, P1J8 and P2J8, moderate on batch P1J5, moderate to fairly clear on batches TJ5, EJ5, P2J5 and fairly clear to clear on batch T0.

[0074] Thus, the PI product induces a decrease in the expression of Nrf2 compared to the control T and the E product.

[0075] The composition according to the invention makes it possible to reduce the expression of Nrf2 in the epidermis. Thus, the reduction in the expression of Nrf2 reflects its translocation from the cytoplasm to the nucleus where it activates genes responsible for cellular protection and in particular the synthesis of antioxidant enzymes. The composition according to the invention therefore has antioxidant properties.

[0076] [Fig.4] illustrates the results of the labeling and therefore of the expression of oxytocin in the epidermis,

[0077] Oxytocin is a hormone synthesized primarily in neurons of the hypothalamic and supraoptic paraventricular nuclei and released into the systemic circulation by the posterior pituitary gland. It is involved in a broad spectrum of tissue-specific activity, including growth and differentiation. cellular, the neuroendocrine response to stress, or even inflammation processes. Within the skin, oxytocin is released following specific stimuli. It can modulate its biological functions via interaction with the oxytocin receptor (OTR / OXTR). This receptor is expressed in keratinocytes and fibroblasts, and high levels of oxytocin have been shown to correlate with younger-looking skin.

[0078] Oxytocin labeling at the epidermis level is low on batches TJ5, EJ5, P1J5 and P2J5, low to moderate on batches TJ8, EJ8, P1J8 and moderate on batches T0 and P2J8.

[0079] Thus, product P2 induces an increase in the expression of oxytocin compared to control T and product E.

[0080] The composition according to the invention makes it possible to increase the expression of oxytocin at the level of the cells of the epidermis. It therefore makes it possible to participate in the growth and proliferation of skin tissue, to fight against inflammation of skin tissue and has anti-aging properties.

[0081] The table below illustrates the results of the ATP assay of batches T0, TJ5, EJ5, P1J5, P2J5, TJ8, EJ8, P1J8 and P2J8.

[0082] [Tables 1] ATP concentration (pmol / g protein) T0 TJ5 EJ5 P1J5 P2J5 TJ8 EJ8 P1J8 P2J8 Mean 0.50 2.37 2.41 2.75 4.15 3.77 3.82 4.45 3.84

[0083] ATP (adenosine triphosphate) is a nucleotide known to stimulate and participate in countless intracellular processes. Extracellular ATP and its metabolite adenosine can exert a variety of effects on almost every cell type in human skin, and potential cutaneous sources of ATP abound. Those in the skin include, for example, ATP released by tissue hypoxia and cell lysis during mechanical injury, ATP release from keratinocytes under the influence of nucleotides or cytokines. ATP promotes keratinocyte proliferation and inhibits terminal keratinocyte differentiation through P2Y2 receptors located in the basal layer of the epidermis.ATP also plays an important role in organizing skin responses to mechanical injury, both by modulating inflammatory processes in Langerhans cells and by directly stimulating skin regeneration and healing processes. ATP is also an important energy molecule for intracellular processes and plays a major role in skin rejuvenation. With aging, ATP levels in the dermis decline, creating an energy deficiency, thus affecting .

[0084]

[0085]

[0086]

[0087]

[0088]

[0089]

[0090]

[0091]

[0092]

[0093]

[0094] the appearance of the skin. Thus, ATP is effective in providing anti-aging protection and also has moisturizing and soothing properties. Thus, we observe that the PI and P2 products induce an increase in the ATP concentration compared to the control T and the E product. The composition according to the invention makes it possible to increase the ATP concentration in the cells of the epidermis. An increase in ATP production in the skin makes it possible to improve the metabolic functions of the skin. The composition according to the invention therefore makes it possible to promote the proliferation and inhibit the terminal differentiation of keratinocytes. The composition according to the invention also makes it possible to participate in the repair of the skin barrier. The inventors also conducted a genomic study to characterize the composition according to the invention. To do this, they prepared human skin explants from an abdominoplasty and divided them into four batches: - the TOg batch corresponding to the plasty control and comprising 3 explants, - the Tg batch corresponding to the control and comprising 6 explants, - batch Eg corresponding to the batch treated with product E and comprising 6 expiants, - batch P 1g corresponding to the batch treated with product PI and comprising 6 expiants, - batch P2g corresponding to the batch treated with product P2 and comprising 6 explants, Each skin explant was kept alive in culture medium at a temperature of 37°C in a humid atmosphere enriched with 5% CO2. At T = 0 days (D0), T = 1 day (D1), T = 5 days (D5), 5 μL of products E, PI and P2 were respectively applied topically to the explants of batches E, PI and P2. On D0, the 3 explants of the TOg batch were collected and cut into three parts. A first and a second part were frozen at -80°C and a third part was stored in a solution to stabilize the RNA (RNAlater) for genomic analysis. At T = 2 days (D2) and T = 6 days (D6), 3 explants from batches Tg, Eg, Plg and P2g were collected and treated in the same way as the explants from batch TOg. RNA samples were then extracted from explants of batches TOg, Tg at D2 (TgJ2) and D6 (TgJ6), Eg at D2 (EgJ2) and D6 (EgJ6), Plg at D2 (PlgJ2) and D6 (PlgJ6) and P2g at D2 (P2gJ2) and D6 (P2gJ6). Each RNA extract was then reverse transcribed, amplified, labeled with Cyanine-3 and hybridized to chips containing the entire human genome in order to perform transcriptomic analysis. Genes modulated in response to PI and P2 products were submitted to the Pre- dictSearch for performing enrichment and identifying biological activities associated with induced or repressed genes.

[0095] It emerges from this genomic study that the PI and P2 products make it possible to modulate numerous genes involved in biological processes such as the skin barrier, keratinocyte migration, antimicrobial response, psoriatic lesions, skin inflammation, epidermal differentiation, healing, lipid metabolism, cell proliferation, DNA repair and lipid mediation.

[0096] The PI and P2 products make it possible to repress a certain number of genes involved in biological processes such as mitophagy, lipid peroxidation, chronic inflammation and terminal differentiation.

[0097] This genomic study confirms the properties of the composition according to the invention that the histological and biochemical studies have revealed.

[0098] The inventors also conducted tests and found that compositions comprising between 10% and 50% by mass of birch sap, between 10% and 50% by mass of maple sap, between 3% and 20% by mass of willow leaf extract and between 3% and 20% by mass of ginkgo biloba leaf extract had the same properties as products PI and P2.

[0099] According to one embodiment of the invention, the composition comprises between 10% and 50% by mass of maple sap (INCI name: Acer Saccharum (Sugar Maple) Sap Extract), for example 12%, 17%, 22%, 27%, 32%, 37%, 42% or 45% by mass.

[0100] According to one embodiment of the invention, the composition comprises between 10% and 50% by mass of birch sap (INCI name: Betula Alba Juice), for example 12%, 17%, 22%, 27%, 32%, 37%, 42% or 45% by mass.

[0101] According to one embodiment of the invention, the composition comprises between 3% and 20% by mass of willow leaf extract (INCI name: Salix Alba (Willow) Leaf Extract), for example 5%, 7%, 9%, 11%, 13%, 15%, 17% or 19% by mass.

[0102] According to one embodiment of the invention, the composition comprises between 3% and 20% by mass of ginkgo biloba leaf extract (INCI name: Ginkgo Biloba Leaf Extract), for example 5%, 7%, 9%, 11%, 13%, 15%, 17% or 19% by mass.

[0103] When the composition according to the invention is combined in a final composition comprising other ingredients, for example cosmetic or dermatological, it is not necessary to add distilled water or preservatives to the final composition.

[0104] The composition according to the invention may also comprise small pepper fruit extract (INCI name: Capsicum Annuum Fruit Extract). This product also has anti-dandruff, antimicrobial, antioxidant, astringent and skin-protecting properties. The composition according to the invention may comprise between 1% and 5% by mass of small chili fruit extract, for example 2%, 3% or 4% by mass.

[0105] The following description relates to examples of compositions according to the invention.

[0106] Example 1: Face serum

[0107] [Tables2] Dénomination INCI Pourcentage massique Acer Saccharum (Sugar Maple) Sap Extract 34,64 Betula Alba Juice 34,64 Salix Alba (Willow) Leaf Extract 8,66 Ginkgo Biloba Leaf Extract 8,66 Tamarindus Indica Seed Gum 2 Glycerin 5 Capsicum Annuum Fruit Extract 2 Hydrolyzed Hyaluronic Acid 1 Sodium Benzoate 0,2 Pentylene Glycol 0,5 Potassium Sorbate 0,2 Xanthan Gum 2 Citric Acid 0,5

[0108] Exemple 2 : Crème visage

[0109] [Tableaux3] Dénomination INCI Pourcentage massique Acer Saccharum (Sugar Maple) Sap Extract 20 Betula Alba Juice 20 Salix Alba (Willow) Leaf Extract 5 Ginkgo Biloba Leaf Extract 5 Glycerin 5 Olive Oil Decyl Esters 5 Cetearyl Olivate 5 Heptyl Undecylenate 2 Sorbitan Olivate 2 Hydrogenated Olive Oil Decyl Esters 4 Corylus Avellana (Hazelnut) Seed Oil 4 Squalane 1 Sodium Stearoyl Glutamate 2 Hexyldecanol 1 Hexyldecyl Laurate 2 Citric Acid 0,5 Prunus Domestica Seed Oil 2 Hydrogenated Olive Oil Unsaponifiables 2 Sodium Benzoate 0,2 Xanthan Gum 1 Lauroyl Lysine 2,5 Squalene 1 Potassium Sorbate 0,2 Pentylene Glycol 0,5 Tamarindus Indica Seed Gum 2 Tocopherol 0,1 Hydrogenated Castor Oil 2,5 Helianthus Annuus (Sunflower) Seed Oil 2,5

[0110] Exemple 3 : Spray pour le corps [OUI] [Tableaux4] INCI name Mass percentage Acer Saccharum (Sugar Maple) Sap Extract 39.9 Betula Alba Juice 39.9 Salix Alba (Willow) Leaf Extract 9.9 Ginkgo Biloba Leaf Extract 9.9 Potassium Sorbate 0.2 Sodium Benzoate 0.2

[0112] Example 4: Body lotion

[0113] [T ableaux5 ] INCI name Mass percentage Acer Saccharum (Sugar Maple) Sap Extract 24.9 Betula Alba Juice 44.9 Salix Alba (Willow) Leaf Extract 14.9 Ginkgo Biloba Leaf Extract 14.9 Potassium Sorbate 0.2 Sodium Benzoate 0.2

[0114] Examples: Body lotion

[0115] [Tableauxô] INCI name Mass percentage Acer Saccharum (Sugar Maple) Sap Extract 44.9 Betula Alba Juice 24.9 Salix Alba (Willow) Leaf Extract 14.9 Ginkgo Biloba Leaf Extract 14.9 Potassium Sorbate 0.2 Sodium Benzoate 0.2

[0116] Example 6: Body serum

[0117] [Tables?] INCI name Mass percentage Acer Saccharum (Sugar Maple) Sap Extract 34.9 Betula Alba Juice 44.9 Salix Alba (Willow) Leaf Extract 9.9 Ginkgo Biloba Leaf Extract 9.9 Potassium Sorbate 0.2 Sodium Benzoate 0.2

[0118] The composition according to the invention may be a cosmetic or dermatological composition. It may be in the form of a gel, a lotion, a mousse, a balm, a cream, a spray or a serum.

Claims

Claims

1. Composition comprising as active ingredient birch sap, maple sap, willow leaf extract and ginkgo biloba leaf extract.

2. Composition according to claim 1, characterized in that it comprises between 10% and 50% by mass of birch sap.

3. Composition according to claim 1 or 2, characterized in that it comprises between 10% and 50% by mass of maple sap.

4. Composition according to any one of the preceding claims, characterized in that it comprises between 3% and 20% by mass of willow leaf extract.

5. Composition according to any one of the preceding claims, characterized in that it comprises between 3% and 20% by mass of ginkgo biloba leaf extract.

6. Composition according to any one of the preceding claims, characterized in that it also comprises extract of small chili fruit.

7. Composition according to one of the preceding characteristics, characterized in that it is in the form of a gel, a lotion, a mousse, a balm, a cream, a spray or a serum.

Images